Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy
Z Xiang, X Deng, W He, Q Yang, L Ni… - Annals of …, 2022 - Taylor & Francis
Background Vascular endothelial growth factor (VEGF) is a critical regulator of malignant
pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and …
pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and …
The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer
Y Chen, NW Mathy, H Lu - Molecular medicine reports, 2018 - spandidos-publications.com
Malignant pleural effusion (MPE) is a severe medical condition, which can result in
breathlessness, pain, cachexia and reduced physical activity. It can occur in almost all types …
breathlessness, pain, cachexia and reduced physical activity. It can occur in almost all types …
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with …
M Tamiya, A Tamiya, H Suzuki, Y Taniguchi… - Investigational new …, 2021 - Springer
Objectives Vascular endothelial growth factor plays an important role in the pathogenesis of
malignant pleural effusion (MPE). We previously showed the efficacy of bevacizumab (Bev) …
malignant pleural effusion (MPE). We previously showed the efficacy of bevacizumab (Bev) …
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East …
K Usui, S Sugawara, M Nishitsuji, Y Fujita, A Inoue… - Lung cancer, 2016 - Elsevier
Background Vascular endothelial growth factor (VEGF) plays a pivotal role in the
pathogenesis of malignant pleural effusion (MPE). Here, a multicenter phase II trial to …
pathogenesis of malignant pleural effusion (MPE). Here, a multicenter phase II trial to …
[HTML][HTML] The role of angiogenesis in malignant pleural effusion: from basic research to clinical application
J Zhao, B Liu, N Liu, B Zhang, X He, Q Ma… - American Journal of …, 2022 - ncbi.nlm.nih.gov
Malignant pleural effusion (MPE) is associated with advanced stages of various malignant
diseases, especially lung cancer, and is a poor prognostic indicator in these patients …
diseases, especially lung cancer, and is a poor prognostic indicator in these patients …
Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion
M Tamiya, A Tamiya, T Yamadori, K Nakao, K Asami… - Medical oncology, 2013 - Springer
Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer
(NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of …
(NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of …
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin–Paclitaxel Treatment for Non …
M Tamiya, A Tamiya, T Yasue, K Nakao… - Anticancer …, 2016 - ar.iiarjournals.org
Aim: Malignant effusion is associated with high serum and plasma levels of vascular
endothelial growth factor (VEGF). There are no biomarkers of outcome for bevacizumab …
endothelial growth factor (VEGF). There are no biomarkers of outcome for bevacizumab …
Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers
RL Sabang, D Gandhiraj, M Fanucchi… - Expert review of …, 2018 - Taylor & Francis
Introduction: Malignant pleural effusion (MPE) is a feature of metastatic cancer associated
with significant morbidity and cost. The typical management of MPE is systemic …
with significant morbidity and cost. The typical management of MPE is systemic …
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
K Kitamura, K Kubota, M Ando, S Takahashi… - Cancer chemotherapy …, 2013 - Springer
Purpose The presence of malignant pleural effusion (MPE) indicates a poorer prognosis for
patients with non-small-cell lung cancer (NSCLC) and impairs their quality of life. Because …
patients with non-small-cell lung cancer (NSCLC) and impairs their quality of life. Because …
Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion
H Tao, Q Meng, M Li, L Shi, J Tang, Z Liu - Thoracic Cancer, 2018 - Wiley Online Library
Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …